Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of SPY072 in Rheumatic Disease

← catalyst calendar

NCT07148414 · readout in 73 d

Sponsored by Spyre Therapeutics, Inc. (industry) · SYRE — their whole pipeline →.

Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
285estimated
Sites
64
Countries
Bulgaria, Czechia, Georgia +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-08-21actualWhen the study began enrolling
Primary completion2026-10-31estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2028-03-31estimatedThe whole study's end, after follow-up
First posted2025-08-29actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-05actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Rheumatic Diseases
  • Rheumatic Joint Disease
  • PsA (Psoriatic Arthritis)
  • AxSpA
  • Rheumatologic Disease

Interventions

  • Drug: SPY002-072 — also filed as SPY072
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)
measured Week 12
Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)
measured Week 16
Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) response
measured Week 16

Permalink · SYRE's whole pipeline · Catalyst calendar · Every registered study · What changed